Lacey, WA − Unigen Pharmaceuticals, Inc., a leading research and development company of proprietary, biologically active plant-derived ingredients recently highlighted novel cosmetic ingredients at the Society of Cosmetic Chemists Technology Showcase in New York City.
Unigen's proprietary PhytoLogix discovery process has yielded botanically derived novel cosmetic ingredients including UP 302, a novel tyrosinase inhibititor that does not contain hydroquinone; Soloprin, a potent anti-oxidation and anti-inflammatory agent; AloeWhite, a water soluble ingredient derived from aloe with skin brightening effects; Uniflavone, a mast cell stabilizer; and I-10, a polysaccharide based immune regulator.
"The cosmetic industry can gain valuable consumer market opportunity through the discovery of bioactive natural compounds," said Qi Jia, PhD, Unigen Chief Science Officer. "Unigen's global collection of therapeutic plants − the world's largest plant library − coupled with our proprietary high-throughput screening and dereplication process offers today's cosmetic leaders the opportunity for truly novel, natural plant derived, science-based compounds."
The company utilizes vertical integration to provide cosmetic industry customers with superior ingredients from safe and consistent raw material farming production and processing. With over 150,000 acres of dedicated farmland and proprietary processing and production, Unigen licenses on an exclusive basis to top cosmetic firms.
"Our science teams focus on actives that are ideal for 'in and out' combination treatments delivering both cosmetic and nutritional benefits," said Doug Lynch, VP Marketing & Sales. "Our novel ingredients are thoroughly tested for safety, and as a global company, Unigen is committed to offer R.E.A.C.H. compliant ingredients."